DiaSorin S.p.A., Epigenomics AG, Techlab, Inc., Positive Biosciences Limited, MedGenome Labs Ltd, and 20/20 GeneSystems, among others are the key players in the global market of cancer screening.
As per the analysis by the Expert Market Research, the global cancer screening market is expected to grow in the forecast period of 2022-2027 at a CAGR of 9%, owing to surging cancer cases globally.
Cancer screening is crucial for identifying the disease before any symptoms develop. It has been projected that the industry will see tremendous growth in the forecast period owing to the increasing cases of cancer. New technologies like liquid biopsy are emerging at a high pace. Next Generation Sequence (NGS) is another technology that has been a focus of many companies as it allows simultaneous sequencing of targeted genomic areas in multiple samples to detect mutations. Such technological advancements are expected to aid the cancer screening market growth.
The expansion of the market is also being driven by the development of improved imaging to recognise the malignant tissues of various cancer types. The need for early detection and treatment of the chronic disease is growing because cancer is one of the main causes of mortality across the globe. Screenings are being utilised more frequently to find malignancies and lower the number of people who die from the disease.
The market is expanding as a result of the application of artificial intelligence (AI) to increase diagnosis speed and accuracy and reduce health disparities in settings with limited resources. Artificial intelligence is being employed in research by numerous organisations, including the National Cancer Institute, fuelling the market's expansion because it can help clinicians make better clinical decisions, detect particular gene mutations, and improve MRI guided biopsies.
When compared to the current standard of care for the early diagnosis of hepatocellular carcinoma (HCC) in patients with liver cirrhosis, Epigenomics' liver cancer panel performed much better, according to a news release issued by the company in April 2021. Patients with cirrhosis who also had early-stage, curable liver cancer were compared to those who only had cirrhosis. According to the study, the new Epigenomics Next Generation Sequencing (NGS) panel obtained a sensitivity of 68% at a specificity of 97% when paired with AFP (alpha-fetoprotein) testing in an ad hoc analysis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Leading the market for laboratory diagnostics worldwide, DiaSorin focuses on immunodiagnostics and molecular diagnostics sectors. They have also been dealing with diagnostics to help patients and physicians make the best decisions during crucial moments. It is a multinational company operating across five continents with around 2,000 employees and more than 200 researchers. Their research and development centres are based in Italy, Germany, and the United States.
The mission of Epigenomics AG is to transform cancer diagnosis through the deployment of novel DNA methylation biomarker technology. They create user-friendly blood-based diagnostic tests for a variety of cancer indications with a significant demand for healthcare. By employing blood for the liquid biopsy, they tend to help remove the most lethal cancers, such as liver, colorectal, and lung cancer, which can increase access to specific cancer screening. They are dedicated towards developing molecular diagnostics tests for cancer. The company’s research and development mission is to improve proprietary technology to maintain leadership in the DNA - methylation-based diagnostics for cancer testing. They use unique DNA methylation biomarkers to market blood-based cancer screening tests.
|Headquarters:||Virginia, United States|
Techlab develops, designs, and manufactures enteric diagnostics that are distributed worldwide. They are working in collaboration with universities and research around the world. They have received 25 patents along with several grant awards. The company's study encompasses markers of intestinal inflammation, the toxins produced by Clostridium difficile, amebiasis, and vaccine development. Its research focuses on enteric diseases and the microbiology of the digestive tract.
The goal of the organisation is to bring the power of knowledge and technology to offer high quality cancer tests for cancer patients and their families. They provide DNA tests for cancer treatment and hereditary cancer screening. The company also uses the latest blood-based liquid biopsy technology to test patients.
|Headquarters:||California, United States|
MedGenome is a company that does research on medication discovery and diagnostics using genetics and clinical data. They are a market leader in India for genetic diagnostics. They additionally employ liquid biopsy tests, an NGS-based ctDNA test offered in India, to track the effectiveness of cancer treatment.
|Headquarters:||Maryland, United States|
The 20/20 GeneSystems Inc. company offers cutting-edge cancer diagnostic and bio-testing techniques that frequently satisfy unmet needs. Better tools are delivered by the company-powered cancer screening tests to improve early identification of the most prevalent cancers worldwide. Emergency responders frequently employ their emergency bio-detection firm, which features a unique BioCheck.
Also Read@ https://www.expertmarketresearch.com/pressrelease/global-cancer-screening-market
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.